Q13153 (PAK1_HUMAN) Homo sapiens (Human)
Serine/threonine-protein kinase PAK 1 UniProtKBInterProSTRINGInteractive Modelling
545 aa; Sequence (Fasta) ; (Isoform 2);
5 identical sequences: Pongo abelii: A0A2J8V0U5; Pan troglodytes: K7DSU6, A0A6D2X6T7; Gorilla gorilla gorilla: G3RY99; Nomascus leucogenys: A0A2I3H6Y7
It is possible new templates exist for this target since these models were created.
Available Structures
32 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1 |
Heteromer | 28×IOD; | ||||
| Assess | ||||||
| Crystal structure of human RAC3 in complex with CRIB domain of human p21-activated kinase 1 (PAK1) |
Heteromer P60763; | 1×MG; 1×GCP; 2×GOL; | ||||
| Assess | ||||||
| beta PIX-SH3 complexed with an atypical peptide from alpha-PAK |
Heteromer Q14155; | |||||
| Assess | ||||||
| Pak1 peptide bound LC8 |
Heteromer Q24117; | |||||
| Assess | ||||||
| Structure of unphosphorylated PAK1 kinase domain | homo-2-mer | 1×MG; 1×ANP; | ||||
| Assess | ||||||
| Serine/threonine-protein kinase PAK1 complexed with a dibenzodiazepine: identification of an allost… | homo-2-mer | 1×4PV; 1×GOL; | ||||
| Assess | ||||||
| The Crystal Structure of PAK1 kinase domain from Biortus. | monomer | |||||
| Assess | ||||||
| Crystal structure of PAK1 in complex with an inhibitor compound 5 | monomer | 1×59N; | ||||
| Assess | ||||||
| Crystal structure of PAK1 in complex with an inhibitor compound G-5555 | monomer | 1×59T; | ||||
| Assess | ||||||
| Crystal structure of P21-activated kinase 1 (PAK1) in complex with compound 9 | monomer | 1×6BZ; | ||||
| Assess | ||||||
| Crystal structure of PAK1 kinase domain with the ruthenium phthalimide complex | monomer | 1×0H2; | ||||
| Assess | ||||||
| Crystal structure of PAK1 kinase domain with ruthenium complex lambda-FL172 | monomer | 1×FLL; | ||||
| Assess | ||||||
| Crystal Structure of PAK1 kinase domain with one point mutations (K299R) | monomer | |||||
| Assess | ||||||
| Crystal Structure of PAK1 kinase domain with two point mutations (K299R, T423E) | monomer | |||||
| Assess | ||||||
| Structure of phosphorylated PAK1 kinase domain | monomer | |||||
| Assess | ||||||
| PAK1 complex with ST2001 | monomer | 1×1ST; | ||||
| Assess | ||||||
| Crystal structure of PAK1 kinase domain in complex with FRAX597 inhibitor | monomer | 1×XR1; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of PAK1 in complex with an inhibitor compound FRAX1036 | monomer | 1×59U; 1×DMS; | ||||
| Assess | ||||||
| Crystal structure of PAK1 kinase domain with ruthenium complex DW1 | monomer | 1×DW1; | ||||
| Assess | ||||||
| Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors | monomer | 1×7KC; | ||||
| Assess | ||||||
| Crystal structure of the kinase domain of human PAK1 in complex with compound 15 | monomer | 1×2K0; | ||||
| Assess | ||||||
| Crystal structure of P21 activated kinase 1 in complex with an inhibitor compound 4 | monomer | 1×4T3; 1×SO4; | ||||
| Assess | ||||||
| Structure of phosphorylated PAK1 kinase domain in complex with ATP | monomer | 1×ATP; 2×MG; | ||||
| Assess | ||||||
| Crystal structure of P21-activated kinase 1 in complex with an inhibitor compound 29 | monomer | 1×4T6; 1×SO4; | ||||
| Assess | ||||||
| P21-activated kinase 1 in complex with a 4-azaindole inhibitor | monomer | 1×C7Y; 1×SO4; | ||||
| Assess | ||||||
| Crystal Structure of p21-activated kinase 1 in complex with an inhibitor compound 17 | monomer | 1×4T5; 2×SO4; | ||||
| Assess | ||||||
| Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors | monomer | 1×2OL; | ||||
| Assess | ||||||
| PAK1 in complex with (S)-N-(tert-butyl)-3-((2-chloro-5-ethyl-8-fluoro-dibenzodiazepin-11-yl)amino)p… | monomer | 1×4OR; | ||||
| Assess | ||||||
| PAK1 in complex with 2-chloro-5-ethyl-8-fluoro-11-(4-methylpiperazin-1-yl)-dibenzodiazepine | monomer | 1×4OQ; | ||||
| Assess | ||||||
| Pak1 in complex with bis-anilino pyrimidine inhibitor | monomer | 1×IPV; | ||||
| Assess | ||||||
| Pak1 in complex with 7-azaindole inhibitor | monomer | 1×IPW; | ||||
| Assess | ||||||
| The crystal structure of PAK1 with the inhibitor GW8510 | monomer | 1×107; | ||||
| Assess | ||||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6fd3.1.A | monomer | 0.83 | 1×ADP; | 94.95 | ||
| Assess | ||||||
| 6byr.2.A | monomer | 0.65 | 27.51 | |||
| Assess | ||||||
2 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 5dfp.1.A | monomer | 0.82 | 97.46 | ||
| Assess | ||||||
| Isoform 2 | 6byr.2.A | monomer | 0.64 | 27.51 | ||
| Assess | ||||||